Zanidatamab plus chemo for advanced HER2-positive bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This phase 3 trial tests whether adding zanidatamab (a targeted antibody) to standard chemotherapy can improve outcomes for advanced HER2-positive biliary tract cancer. If you have this type of cancer that has spread or can't be removed, and you've had little or no prior treatment, this study might be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed biliary tract cancer (gallbladder or bile duct cancer) that has spread or cannot be removed by surgery.
- You can have received no more than 2 cycles of a specific chemotherapy combination (cisplatin and gemcitabine) with or without an immunotherapy drug for your advanced cancer.
- Your tumor must be HER2-positive, a type that may be targeted by the study drug.
- You must be in good overall health (able to do most daily activities).
- You cannot have had previous treatment with a HER2-targeted drug or certain other immunotherapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for people with HER2-positive bile duct or gallbladder cancer that has grown after first treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of three drugs (disitamab vedotin, lenvatinib, and a PD-1 inhibitor) for people with advanced bile duct cancer that has a protein called HER2. The goal is to see if this treatment can shrink or control the cancer.
This study tests a new combination of drugs for advanced bile duct cancer that has not been treated yet and shows a protein called HER2. It compares the new combination to the standard treatment to see if it works better or has fewer side effects.
This trial tests if adding trastuzumab to standard chemotherapy can help people with advanced bile duct or gallbladder cancer that tests positive for HER2. The study aims to see if the combination works better than chemotherapy alone.
This trial tests a combination of chemotherapy, immunotherapy, and heat therapy (hyperthermia) with a special radiation technique for advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination can help shrink tumors and improve outcomes.
This trial tests a combination of trastuzumab (a HER2-targeted drug), serplulimab (an immunotherapy), and chemotherapy for people with advanced bile duct or bladder cancer that is HER2-positive and has not responded to prior treatments. The goal is to see if this mix can shrink tumors or slow the disease.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.